GSK, XenoPort revise Horizant pact

Just a few days after the FDA accepted GlaxoSmithKline's ($GSK) response to its complete response letter on Horizant for review, XenoPort ($XNPT) announced that it had revised its development pact with GSK on the new therapy for restless leg syndrome. XenoPort retrieved ex-U.S. rights to the therapy, while leaving GSK in charge of the U.S. market. In a statement the developer also said that the two partners had revised the terms of the deal, but no numbers were outlined. The FDA had rejected Horizant after noting signs of cancer in a rat study. XenoPort release

Suggested Articles

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.

AbbVie and Roche alum Janet Hammond, M.D., Ph.D., Sc.M., F.C.P. has nabbed the chief development officer role at infectious disease biotech Atea.